Latest Market Integrity News

Unith Ltd has responded to an ASX price query following unusual trading activity, denying undisclosed information and pointing to a successful recent roadshow as a potential factor.

The Takeovers Panel has issued interim orders compelling Emu NL to submit all proxy forms from its recent extraordinary general meeting, including those disallowed, as part of an ongoing dispute initiated by Wayburn Holdings.

The ASX has formally queried Bougainville Copper Limited following an unexpected surge in its share price and trading volume, seeking clarity on any undisclosed information that might explain the market activity.

Mount Burgess Mining has applied to the Supreme Court of Western Australia for orders to validate previous share sales and extend deadlines for cleansing notices, aiming to shield sellers from civil liability. The hearing is set for 19 May 2025.

Celsius Resources has successfully completed the second tranche of its capital raising, issuing over 227 million shares and securing approximately A$1.75 million. The new shares are now trading on AIM, marking a significant step in the company’s funding strategy.

Resource Mining Corporation Limited (RMI) has responded to a sharp surge in its share price and trading volume, denying any undisclosed material information while pointing to ongoing copper-gold exploration activities at its Mpanda Project in Tanzania.

Mount Burgess Mining NL has voluntarily suspended trading of its shares on the ASX pending a court ruling on the validity of a recent cleansing notice tied to new share issuance.

Holista Colltech Limited has responded to an ASX price query regarding recent unusual trading activity, confirming no undisclosed material information exists to explain the surge.

Raptis Group Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant share placement and entitlement offer, signaling a pivotal moment for the company’s capital structure.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.

An application to the Takeovers Panel challenges Pact Group Holdings’ planned ASX delisting, citing concerns over shareholder disadvantage and selective disclosure.